What Does Prednisone Do for a Respiratory Infection?

Prednisone dials down the immune system’s inflammatory response in the airways, which can relieve swelling, reduce mucus production, and help you breathe more easily during certain respiratory infections. But whether that inflammation-dampening effect actually helps depends heavily on the type of infection, its severity, and your underlying health. In conditions like COPD flare-ups, asthma attacks triggered by infection, severe pneumonia, and childhood croup, prednisone has solid evidence behind it. For a run-of-the-mill chest cold, it does essentially nothing, and in some viral infections like influenza, it can make things worse.

How Prednisone Works in the Airways

When you have a respiratory infection, your immune system ramps up inflammation to fight the invading pathogen. That response involves a cascade of signaling molecules, and in many cases the inflammation itself becomes the bigger problem. Swollen airways, excess mucus, and tissue damage from your own immune cells can make breathing difficult even as the infection clears. Prednisone, a synthetic corticosteroid, works by suppressing the inflammatory signals that drive this process. It blocks key molecular switches that tell cells to produce inflammatory proteins like cytokines, adhesion molecules, and inflammatory enzymes.¹ At the genetic level, it essentially reverses the process that turns on inflammatory genes, restoring them to a quieter state.²

That broad anti-inflammatory reach is what makes prednisone so useful across different respiratory conditions and so potentially harmful in the wrong context. It doesn’t target just the “bad” inflammation; it turns down the immune response across the board. When excessive inflammation is what’s making you sick, that’s a net win. When you need your immune system firing on all cylinders to clear a virus, blunting it can be counterproductive.

COPD Exacerbations

Flare-ups of chronic obstructive pulmonary disease are one of the best-studied uses of prednisone in respiratory illness. People with COPD already have chronically inflamed, narrowed airways, and an infection or irritant can tip them into a crisis where breathing becomes severely limited. A short course of prednisone reduces the swelling enough to open the airways back up. In a randomized trial of patients treated in the emergency department for COPD exacerbations, those given prednisone had a relapse rate of about 27 percent at 30 days compared with 43 percent in the placebo group, and their lung function improved roughly twice as much over the treatment period.³

Current guidelines generally recommend a short oral corticosteroid course, typically around five to ten days, for moderate to severe COPD flare-ups. The benefit is clearest when the exacerbation involves significant airway inflammation rather than purely infectious symptoms. That distinction has led researchers to look for ways to predict who will respond best, which we’ll get to shortly.

Asthma Attacks Triggered by Infection

Respiratory infections are one of the most common triggers of asthma exacerbations, and prednisone has been a cornerstone of treatment for decades. The logic is similar to COPD: the underlying disease involves chronic airway inflammation, and an infection piles on more. A short burst of prednisone can prevent the kind of spiraling airway constriction that sends people back to the emergency room. In a trial comparing prednisone to placebo after emergency treatment of acute asthma, patients who received a short course had significantly fewer relapses, with only about 6 percent returning compared with roughly a quarter of the placebo group over the first ten days.⁴

This is one setting where the evidence is strong enough that withholding corticosteroids from a genuine asthma flare-up would be hard to justify. The question isn’t whether prednisone helps in acute asthma, it’s how to keep courses short and infrequent to avoid the cumulative side effects discussed below.

Severe Community-Acquired Pneumonia

Pneumonia is where the picture gets more nuanced. Not all pneumonia warrants corticosteroids, but in severe cases, particularly when the body’s inflammatory response has become dangerously overblown, a short course can speed recovery. A review of trials in severe community-acquired pneumonia found that corticosteroids shorten the time to clinical stability by about 1.2 days and reduce hospital stays by roughly a day.⁵ Those numbers may sound modest, but in a hospitalized patient struggling to breathe, getting to stable condition even one day sooner can matter.

The trade-off is that corticosteroids increase the frequency of high blood sugar requiring treatment in these patients, though they don’t appear to raise the risk of gastrointestinal bleeding.⁵ For milder pneumonia managed at home, the benefit-risk balance tilts the other way, and guidelines generally don’t recommend routine corticosteroid use in those cases.

Why It Does Not Help Ordinary Coughs and Colds

This is the gap between what many people expect prednisone to do and what it actually does. If you visit a doctor with a nasty cough from a standard lower respiratory tract infection, the kind caused by common viruses that doesn’t require hospitalization, prednisone won’t help you get better any faster. The OSAC trial (Oral Steroids for Acute Cough) tested prednisolone against placebo in adults with acute lower respiratory tract infections who didn’t have diagnosed asthma. The result was striking in its lack of effect: median cough duration was three days in both the steroid and placebo groups, and symptom severity scores were virtually identical.⁶

Despite this evidence, prednisone prescriptions for uncomplicated respiratory infections remain common. Part of the issue is that patients often feel terrible and want something stronger than over-the-counter remedies, and clinicians sometimes prescribe steroids as a gesture of action. But when the underlying problem is an infection that the immune system can handle on its own, suppressing inflammation doesn’t speed recovery and exposes you to side effects for no benefit.

The Influenza Problem

If prednisone is merely useless for mild respiratory infections, with influenza it can be actively harmful. This is one of the most important distinctions for both patients and clinicians. A systematic review and meta-analysis of corticosteroid use in influenza pneumonia found that steroids were associated with about 75 percent higher mortality, longer ICU stays, and roughly double the rate of secondary bacterial infections compared with patients who didn’t receive them.⁷ Another review confirmed this pattern, noting that higher doses and longer courses were particularly problematic, with associations including delayed viral clearance and more secondary pneumonia.⁸

The mechanism makes intuitive sense once you know how prednisone works. Influenza triggers an aggressive immune response, but unlike the out-of-control inflammation seen in severe bacterial pneumonia or COPD flare-ups, the immune system in many flu patients needs to stay active to clear the virus. Suppressing it with corticosteroids gives the virus more room to replicate and leaves the lungs vulnerable to opportunistic bacteria. This is a case where the “off switch” for inflammation backfires badly.

Lessons from COVID-19

The pandemic provided a massive, high-stakes natural experiment in corticosteroid use. Early on, clinicians were uncertain about whether steroids would help or harm COVID-19 patients. The RECOVERY trial, one of the largest randomized trials in the pandemic, gave a clear answer, but it came with a critical nuance. Among hospitalized patients given dexamethasone (a corticosteroid closely related to prednisone), 28-day mortality dropped meaningfully. The benefit was largest in patients on mechanical ventilation, where the death rate fell from about 41 percent to 29 percent, and was still present in patients receiving supplemental oxygen.⁹

But among patients who weren’t sick enough to need respiratory support, dexamethasone didn’t reduce mortality and may have slightly increased it.⁹ Another study found that when corticosteroids were given within the first week of hospital admission, they were associated with reduced mortality and fewer transfers to the ICU.¹⁰ The lesson echoed what was already known from other respiratory conditions: corticosteroids help when inflammation has become the dominant threat, not when the infection itself is still the main problem. Timing and severity are everything.

Croup in Children

If there’s one respiratory condition where corticosteroids are a near-universal recommendation, it’s croup. This common childhood illness, caused by viral infection of the upper airway, produces the characteristic barking cough and stridor (that harsh sound when a child breathes in) because the trachea and larynx swell significantly. A child’s airway is small enough that even modest swelling can cause serious breathing difficulty.

A single oral dose of dexamethasone at 0.6 mg/kg is considered highly effective for treating croup symptoms across all severity levels.¹¹ The evidence for this is unusually robust for a pediatric condition. In children with severe croup needing intensive care, corticosteroid treatment reduced the need for intubation fivefold. In children admitted to the hospital with moderate to severe croup, treatment cut admission rates by half. And even in mild croup, a single dose of corticosteroid halved the rate of return medical visits and reduced parental stress and sleep loss.¹² Unlike many of the adult conditions discussed above, the benefit here is consistent regardless of how mild or severe the croup is, making it one of the most straightforward uses of corticosteroids in respiratory medicine.

Who Responds Best and the Role of Blood Eosinophils

One of the more interesting developments in steroid prescribing is the idea that a simple blood test could predict whether you’ll benefit from prednisone during a respiratory flare-up. Eosinophils are a type of white blood cell closely associated with allergic and inflammatory responses in the airways. When eosinophil counts are elevated during a COPD exacerbation, it signals a type of inflammation that corticosteroids are particularly good at targeting.

A large UK-based trial tested this idea directly. Patients with COPD exacerbations whose blood eosinophil counts were high showed significantly greater improvement in lung function when treated with prednisolone compared with those who had low eosinophil counts.¹³ In a smaller asthma study, adjusting steroid doses based on eosinophil levels reduced exacerbation frequency while actually lowering the overall steroid dose patients needed.¹⁴

This matters because it points toward a future where prednisone prescribing for respiratory infections becomes more targeted. Instead of giving every COPD patient a steroid burst during a flare-up, a quick blood test could identify the subset who will truly benefit, sparing the rest from unnecessary drug exposure. That approach is still being adopted into routine practice, but the evidence is compelling.

Short-Term Side Effects You Should Expect

Even a short course of prednisone, the typical five-to-ten-day burst used for most respiratory conditions, can produce noticeable side effects. The most common is elevated blood sugar, which in the severe pneumonia trials was frequent enough to require treatment.⁵ If you have diabetes or prediabetes, your doctor should be monitoring your glucose more closely while you’re on prednisone.

Other short-term effects that catch people off guard include insomnia, mood changes (ranging from feeling wired and restless to outright irritability or anxiety), increased appetite, and sometimes a metallic taste. These tend to resolve once the course ends, but they can be unpleasant enough that patients abandon the course early if they weren’t warned. The mood effects are real and well-documented, not a sign that something has gone wrong, but worth knowing about in advance.

One concern that comes up frequently is whether corticosteroids during a respiratory infection raise the risk of secondary bacterial infections. In critically ill COVID-19 patients, one study found no statistically significant increase in the likelihood of secondary infection when adjusting for other factors.¹⁵ However, as noted earlier, the influenza data tells a different story, with corticosteroids roughly doubling secondary infection rates in that context.⁷ The infection risk appears to depend on which pathogen you’re fighting and how long the steroid course lasts.

The Cumulative Burden of Repeated Short Courses

Here’s something that often gets lost in the conversation about “just a short course of prednisone.” Each individual burst may be brief, but for people with conditions like asthma or COPD who get several courses a year, the total lifetime exposure adds up. A large matched-cohort study found a dose-response relationship between cumulative oral corticosteroid exposure and adverse effects, with problems like osteoporosis, high blood sugar, and muscle weakness appearing at exposures as low as roughly four lifetime courses.¹⁶ These effects were present even when individual courses lasted less than a week.

This finding challenges the casual attitude many clinicians and patients have toward short steroid bursts. A single five-day course for a bad COPD exacerbation is one thing. Getting three or four of those a year, year after year, accumulates into a meaningful drug burden. It’s one of the strongest arguments for better disease control, whether through inhaled corticosteroids, biologics, or other preventive strategies, so that systemic steroid bursts become rare events rather than a regular occurrence.

Inhaled Steroids as a Lower-Risk Alternative

For COPD exacerbations specifically, researchers have tested whether inhaled corticosteroids, which deliver the drug directly to the airways rather than flooding the entire body, might work as well as oral prednisone with fewer systemic side effects. A systematic review and meta-analysis found that the two approaches produced similar outcomes for treatment failure, breathlessness, and serious adverse events. The key difference was in side effects: systemic corticosteroids caused significantly more high blood sugar episodes, while inhaled steroids caused more oral fungal infections (thrush), a local side effect of the delivery method.¹⁷

For someone with diabetes or at risk of steroid-induced blood sugar spikes, the inhaled route might be preferable during a COPD flare-up. But inhaled steroids haven’t replaced oral prednisone as the default for most other respiratory conditions, partly because the evidence is specific to COPD exacerbations and partly because severely inflamed airways may not distribute an inhaled drug effectively. When you can barely move air through your lungs, an oral pill reaches the target tissue more reliably.

Dosing and Whether You Need to Taper

The typical prednisone course for a respiratory exacerbation is in the range of 20 to 40 mg per day for five to ten days. Patients often worry about whether they need to gradually reduce the dose at the end rather than stopping abruptly. For short courses, the evidence suggests it doesn’t matter. A study comparing a flat 40 mg daily dose of prednisolone for eight days against a tapering course starting at the same dose found no difference in lung function recovery, relapse rates, or adrenal suppression between the two approaches.¹⁸

Tapering becomes important when courses last longer than about two weeks, or when someone has been on repeated short courses close together, because the body’s own cortisol production shuts down during steroid treatment and needs time to restart. For the standard five-to-ten-day burst used in most acute respiratory situations, abrupt discontinuation is generally fine. If your doctor sends you home with a prednisone pack and doesn’t mention tapering, that’s usually intentional, not an oversight.

When Prednisone Gets Prescribed Unnecessarily

One of the persistent problems in respiratory medicine is the overuse of systemic corticosteroids for conditions where they offer no proven benefit. Acute bronchitis, the common cold with a lingering cough, mild viral upper respiratory infections: these account for a substantial number of prednisone prescriptions despite the absence of evidence that the drug helps. The OSAC trial data showing zero benefit in uncomplicated lower respiratory infections has been available for years, yet prescribing habits change slowly.⁶

If you’re prescribed prednisone for a respiratory infection, it’s worth asking your doctor what the specific indication is. Are they treating an asthma flare-up that the infection triggered? A COPD exacerbation? Severe pneumonia with marked inflammation? Those are legitimate uses. If the answer is simply “you have a bad cough and this should help,” the evidence says it won’t, and you’d be accepting side effects and cumulative steroid exposure for nothing in return. Being an informed patient in this situation can spare you an unnecessary drug course and the insomnia and jitteriness that come with it.

1
European Respiratory Journal. Corticosteroid effects on cell signalling
2
PubMed Central. How corticosteroids control inflammation: Quintiles Prize Lecture 2005
3
PubMed. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease
4
PubMed. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma
5
PubMed Central. Corticosteroids in severe community-acquired pneumonia: friend, foe or both?
6
PubMed Central. Oral prednisolone for acute lower respiratory tract infection in clinically unrecognised asthma: an exploratory analysis of the OSAC randomised controlled trial
7
PubMed Central. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis
8
PubMed Central. The role of corticosteroids in severe viral pneumonia: lessons from COVID-19 and influenza
9
PubMed. Dexamethasone in Hospitalized Patients with Covid-19
10
BMJ Open Respiratory Research. Impact of corticosteroids in hospitalised COVID-19 patients
11
PubMed Central. Acute management of croup in the emergency department
12
CMAJ. Croup in children
13
The Lancet Respiratory Medicine. Blood eosinophil-guided oral prednisolone for acute exacerbations of chronic obstructive pulmonary disease in primary care in the UK (STARR2): a randomized, double-blind, placebo-controlled, non-inferiority trial
14
PubMed. Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma
15
PubMed Central. The Impact of Corticosteroids on Secondary Infection and Mortality in Critically Ill COVID-19 Patients
16
European Respiratory Journal. Recognising the long-term burden of short course oral corticosteroids
17
PubMed Central. Inhaled versus systemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis – Section: Results
18
PubMed. A comparison of non-tapering vs. tapering prednisolone in acute exacerbation of asthma involving use of the low-dose ACTH test